Previously dba Fusologics LLC, Zetagen is a clinical-stage, biopharmaceutical company driving breakthrough innovation in the areas of metastatic bone cancer treatments and osteologic interventions. The firm's multi-patented, ZetaMet technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. With the platform technology exclusively-licensed from the State University of New York in 2016, the novel therapy -- a drug-eluting implant technology -- has successfully passed its preclinical trials and began its first human clinical trial in Q4 2021. In addition to ZetaMet, the Companys pipeline includes other oncologic treatments for Skeletal Related Events (SREs), i.e., ZetaMet Flowable and ancillary osteologic treatments including, ZetaFuse, ZetaSet, ZetaDent and ZetaBase
